D. Ruiter

发表

G. V. van Muijen, C. M. Ferrier, D. Ruiter, 1998, Annals of medicine.

Identification of multiple mRNA and DNA sequences from small tissue samples isolated by laser-assisted microdissection.

C. Figdor, G. Adema, G. V. van Muijen, 1998, Laboratory investigation; a journal of technical methods and pathology.

A. Paradiso, P. Johnston, A. Eggermont, 2022 .

In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients

C. Figdor, C. Punt, G. Adema, 2007, Cancer Immunology, Immunotherapy.

Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.

P. Quax, H. Verspaget, U. Weidle, 1994, The American journal of pathology.

The eortc melanoma group exchange program: Evaluation of a multicenter monoclonal antibody study

E. Bröcker, U. Kleeberg, J. Doré, 1991, International journal of cancer.

Expert review remains important in the histopathological diagnosis of cutaneous melanocytic lesions

L. Kiemeney, K. Aben, A. Klaasen, 2007, Histopathology.

Emergence of α5β1 fibronectin‐ and αvβ3 vitronectin‐receptor expression in melanocytic tumour progression

E. Danen, E. Bröcker, D. Ruiter, 1994 .

Variations in histopathological evaluation of nonneoplastic colonic mucosal abnormalities; assessment and clinical significance

P. Hoedemaeker, J. Hermans, D. Ruiter, 1985, Histopathology.

The plasminogen activation system in tumour invasion and metastasis.

G. V. van Muijen, D. Ruiter, T. D. de Vries, 1996, Pathology, research and practice.

Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR

T. Wobbes, C. Punt, L. T. van de Locht, 1999, British Journal of Cancer.

Analysis of melanoma cells in peripheral blood by reverse transcription‐polymerase chain reaction for tyrosinase and MART‐1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method

C. Punt, G. V. van Muijen, D. Ruiter, 2000, Melanoma research.

Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.

A. V. van Kessel, G. Adema, G. V. van Muijen, 2000, Cancer research.

Properties of metastasizing and nonmetastasizing human melanoma cells.

P. Quax, E. Danen, J. Verheijen, 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma

U. Weidle, G. V. van Muijen, D. Ruiter, 2001, Melanoma research.

High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.

G. V. van Muijen, D. Ruiter, T. D. de Vries, 1998, British Journal of Cancer.

Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation

P. Quax, L. Lund, K. Danø, 1991, The Journal of cell biology.

Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871)

E. Bröcker, U. Kleeberg, S. Suciu, 1999 .

Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852.

E. Bröcker, P. Rümke, M. von Depka Prondzinski, 1993, Melanoma research.

Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.

U. Weidle, J. Verheijen, G. V. van Muijen, 1996, Cancer research.

Immunohistochemistry in melanocytic proliferative lesions

G. V. van Muijen, D. Ruiter, G. V. van Muijen, 2004, Histopathology.

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis.

D. Schadendorf, A. Eggermont, D. Ruiter, 2004, European journal of cancer.

Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions — a minireview

U. Weidle, D. Ruiter, G. Muijen, 1996 .

N-ras mutations in human cutaneous melanoma from sun-exposed body sites

L. J. Veer, R. Versteeg, J. Bos, 1989, Molecular and cellular biology.

E‐cadherin expression in human melanoma

E. Danen, G. V. van Muijen, R. Morandini, 1996, Melanoma research.

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a

A. Eggermont, J. Thompson, A. Eggermont, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognoses and surgical treatment of patients with stage I melanomas of the skin: A retrospective analysis of 211 patients

D. Ruiter, J. Hermans, K. Welvaart, 1986, Journal of surgical oncology.

Fibrinolytic activity in aneurysmal bone cysts.

V. N. Hegt, F. Haverkate, D. Ruiter, 1975, American journal of clinical pathology.

Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue

C. Sweep, H. Straatman, C. M. Ferrier, 1999, British Journal of Cancer.

Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

T. Wobbes, G. V. van Muijen, D. Ruiter, 1997, Cancer research.

Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas.

D. Elder, A. Spatz, R. Barnhill, 2003, European journal of cancer.

Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays

U. Weidle, T. V. van Kuppevelt, G. V. van Muijen, 2005, British Journal of Cancer.

Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.

P. Quax, U. Weidle, M. Ploug, 1994, Annales de biologie clinique.

The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European Organization for Research and Treatment of Cancer.

A. Eggermont, A. Testori, U. Keilholz, 2001, Annals of surgical oncology.

3 Adjuvant phase III trial (EORTC 18871) with RIFN-alpha 2B versus RIFNgamma versus Iscador versus observation for melanoma patients after surgery for high risk primary (>3 mm) or regional lymph node metastasis

A. Eggermont, E. Bröcker, U. Kleeberg, 2004 .

The plasminogen activation system in melanoma cell lines and in melanocytic lesions.

G. V. van Muijen, D. Ruiter, T. D. de Vries, 1996, Melanoma research.

The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. European Organisation for Research and Treatment of Cancer.

A. Eggermont, P. Autier, U. Keilholz, 2002, European journal of cancer.

Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood

C. Punt, D. Ruiter, G. Muijen, 1999, British Journal of Cancer.

The AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group.

A. Eggermont, A. Testori, C. Punt, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Improved resolution by mounting of tissue sections for laser microdissection

M. Bernsen, H. Dijkman, D. Ruiter, 2003, Molecular pathology : MP.

Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays

U. Weidle, H. Burtscher, G. V. van Muijen, 2002, Melanoma research.

EXPRESSION AND SUSCEPTIBILITY TO MODULATION BY INTERFERONS OF HLA CLASS I AND II ANTIGENS ON MELANOMA CELLS. IMMUNOHISTOCHEMICAL ANALYSIS AND CLINICAL RELEVANCE

D. Ruiter, E. Bröcker, S. Ferrone, 1986, Journal of immunogenetics.

Increased expression of cytokeratins 8, 18 and vimentin in the invasion front of mucosal squamous cell carcinoma

D. Ruiter, H. Schaafsma, F. Ramaekers, 1993, The Journal of pathology.

Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney

D. Ruiter, U. Jonas, P. Hoedemaeker, 1986, International journal of cancer.

High tPA-expression in primary melanoma of the limb correlates with good prognosis

A. Eggermont, U. Kleeberg, H. Straatman, 2000, British Journal of Cancer.

Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis.

B. Nielsen, D. Ruiter, M. Schmitt, 1998, European journal of cancer.

Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study.

A. Eggermont, D. Ruiter, A. Eggermont, 1996, British Journal of Cancer.

Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression

D. Ruiter, D. Ruiter, I. Cornelissen, 1999, British Journal of Cancer.